Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: A series of 4 cases

Allan C. Gelber, Hossein C. Nousari, Fredrick M. Wigley

Research output: Contribution to journalArticle

Abstract

Four cases with classic skin manifestations and histologic evidence of dermatomyositis are presented. No occult malignancies were found. After conventional therapy with corticosteroids, hydroxychloroquine and/or methotrexate proved to be limited by side effects or an inadequate clinical response, a therapeutic trial of mycophenolate mofetil was instituted. This relatively new drug, which inhibits lymphocyte proliferation, was effective [with a mean duration of treatment of 13 months (range 6-20)] at controlling cutaneous disease activity, resulting in a decrease of the steroid dose.

Original languageEnglish (US)
Pages (from-to)1542-1545
Number of pages4
JournalJournal of Rheumatology
Volume27
Issue number6
StatePublished - Jun 26 2000

Keywords

  • Dermatomyositis
  • Mycophenolate mofetil

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: A series of 4 cases'. Together they form a unique fingerprint.

  • Cite this